Conviction: Medium
Status: Researching — RSI 17.4 (data as of 02/23), continued extreme; approaching Feb 12 capitulation low
Quick Snapshot
| Signal |
Reading |
| Overall |
🔴 RSI 17.4 (last OHLC: 02/23) — sustained extreme oversold. Price $162.31, 7D improved slightly (-1.3% vs prior -8.4%), -32.2% in 30 days. SMA20 $195.64. No sustained recovery forming. |
| Moat |
Wide |
| Key insight |
IQV OHLC data last updated 02/23. The -1.3% 7D (vs prior -8.4%) shows the pace of decline may be slowing. RSI at 17.4 has been sustained for 3+ weeks now without recovery — the longest extreme RSI streak in our coverage. Price at $162.31 is approaching the Feb 12 capitulation intraday low ($156.67). If that breaks, $136 (April 2025 52wk low) is next. Key signal to watch: RSI stabilizing above 20 for 3+ consecutive days. |
Action Matrix
| Action |
Level |
Why |
| Current |
🔍 Research / Watch |
RSI stuck at extreme but no stabilization signal yet. Falling knife risk. |
| Entry Zone |
$155 - $170 |
Current $162.31 — in zone, but downtrend may continue |
| Stop-Loss |
$134 (-17%) |
Below April 2025 52-week low ($135.97) |
| Target |
$217 (+34%) |
Return to 3-month mean; conservative vs $244 highs |
Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| IQV |
$162.31 |
-2.0% |
-1.3% |
-32.2% |
— |
-32.7% |
17↓ |
🔴 Extreme Oversold |
🔍 Watch |
Note: OHLC data last updated 2026-02-23. RSI 17.4, SMA20 $195.64.
Legend
- RSI
↓ = Oversold (<30) — potential buying opportunity (but watch for continued deterioration)
- 52wkHi = -32.7% from $241.04 in-window peak
- 52wk Low = $135.97 (Apr 9, 2025)
- SMA20 = $195.64 (price is -17.0% below SMA)
Price vs Last Deep Dive (02/26)
| Metric |
02/26 |
03/03 |
Change |
| Price |
$162.31 |
$162.31 |
$0.00 (data stale since 02/23) |
| RSI |
17.4 |
17.4 |
0.0 (stale) |
| SMA20 |
$195.64 |
$195.64 |
Unchanged (stale) |
| vs SMA |
-17.0% |
-17.0% |
Stale |
Update (03/03): IQV OHLC has not refreshed beyond 02/23. No recovery signal visible. The 7D reading (-1.3%) is better than the -8.4% 7D seen on 02/26, suggesting the pace of decline may be slowing — but with stale data it's hard to confirm. RSI 17.4 has been sustained for over 3 weeks. The critical test remains: does the $156.67 Feb 12 low hold?
Company Overview
One-Liner
IQVIA provides data analytics, technology solutions, and contract research services to the life sciences industry.
Business Model
| Question |
Answer |
| What they sell |
Clinical trial management (CRO), healthcare data/analytics, technology platforms, commercial services |
| Who pays |
Pharma companies (90% of top 25 are clients), biotech firms, medical device companies, government agencies |
| Revenue model |
Long-term contracts (CRO), SaaS subscriptions (analytics), project-based (consulting) |
| How sticky |
Very high — multi-year CRO contracts, deeply embedded analytics platforms, proprietary data moat |
Key Segments
| Segment |
Revenue % |
Growth |
Notes |
| R&D Solutions (R&DS) |
55% |
+4.3% YoY |
Clinical trial management — $8,896M in 2025 |
| Technology & Analytics (TAS) |
40% |
+7.6% YoY |
Cloud apps, real-world evidence, data analytics — $6,626M in 2025 |
| Contract Sales & Medical (CSMS) |
5% |
Flat |
Merging into TAS in 2026 |
Competitive Analysis
Competitive Moat
| Moat Type |
Present? |
Evidence |
| Network effects |
🟢 |
More data from trials = better analytics = attracts more clients |
| Switching costs |
🟢 |
Multi-year contracts, deeply embedded platforms, proprietary data dependencies |
| Cost advantages |
🟢 |
Scale across 100+ countries, largest CRO workforce globally |
| Intangible assets |
🟢 |
Proprietary healthcare datasets covering 1B+ patient records, regulatory expertise |
| Efficient scale |
🟢 |
$16.3B revenue vs ICON's $7.8B — economies of scale in trial management |
Moat Width: Wide
Moat Trend: Widening (AI + data flywheel)
Financials Summary
| Metric |
2025 |
2024 |
Trend |
| Revenue |
$16,310M |
~$15,480M |
📈 +5.4% |
| Adj. EPS |
$11.92 |
$11.13 |
📈 |
| Net Debt/EBITDA |
~3.4x |
~3.5x |
📈 Deleveraging |
Valuation
| Metric |
Current |
5Y Avg |
Signal |
| P/E (trailing) |
~14x |
~50x |
🟢 Near 5Y floor |
| P/E (forward) |
~13x |
~25x |
🟢 |
| EV/EBITDA |
~10x |
~15x |
🟢 |
Fair Value Estimate: $210-$230 (based on 16-18x forward EPS of $12.70 midpoint guidance)
Bull Case
Why This Could Work
- Extreme valuation compression — Trading at ~13x forward P/E vs 5Y avg ~25x. Near 5Y lows.
- AI/agentic platform catalyst — Strategic AWS partnership, deploying agentic AI across clinical trials.
- Irreplaceable data moat — 1B+ patient records, 33% health analytics share, 90% of top pharma are clients.
- CRO market tailwinds — CRO market growing at 8.3% CAGR to $126B by 2030.
- 100% earnings beat rate — Every quarter for 4+ years.
Bear Case
What Could Go Wrong
- Clinical trial cancellations accelerating — Biotech funding pullback leads to more cancellations.
- Debt burden — ~$13B debt with $80M step-up in interest expense in 2026.
- 2026 EPS guidance below expectations — $12.55-$12.85 guidance disappointed consensus.
- Competition from specialized AI analytics — New entrants with superior AI capabilities.
Thesis Killers
- R&DS backlog declining for 3+ consecutive quarters
- Major pharma client defecting to competitor
- Debt covenant breach or downgrade to junk
Entry Strategy
Technical Levels
| Level |
Price |
Notes |
| Support 1 |
$157 |
Feb 12 intraday low area — KEY level being tested |
| Support 2 |
$136 |
April 2025 52-week low — next stop if support fails |
| Resistance 1 |
$187 |
Feb 6 close (post-earnings) |
| Resistance 2 |
$195.64 |
SMA20 |
| 52-week high |
$241.04 |
In-window high |
| 52-week low |
$135.97 |
Apr 9, 2025 |
Entry Approach
| Strategy |
Details |
| Entry trigger |
RSI stabilizes above 20 for 3+ consecutive days |
| Starter position |
1% of portfolio |
| Add on |
Stabilization above $175 with RSI > 25 |
| Full position at |
Confirmation of Q1 2026 guidance being met |
Research Log
| Date |
Update |
| 2026-02-15 |
Created deep dive. RSI 14 extreme oversold. -31% 30D on guidance miss. Wide moat, 100% earnings beat rate, fair value $210-$230. |
| 2026-02-22 |
Price refresh. Price $165.62 (-0.8% from 02/15). RSI improved from 14 to 25.5 — stabilization. 30D still -31.4%. SMA20 $199.29. Still in research/watch mode. |
| 2026-02-26 |
Price deteriorated. $162.31 (-2.0% from 02/22). RSI slipped from 25.5 → 17.4 (reversal of recovery). -8.4% in 7 days, -32.2% in 30 days. No stabilization forming. Approaching Feb 12 low ($156.67). Status: Research/Watch. |
| 2026-03-03 |
OHLC stale (last entry 02/23). Data shows same $162.31, RSI 17.4. 7D improved to -1.3% (vs prior -8.4%) — possible slowing of decline. RSI at 17.4 for 3+ weeks is the longest extreme streak in our coverage. No entry signal yet. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI 14 → 25 → 17 (failed recovery) |
Sustained institutional selling; no bottom formed yet |
| 3+ weeks at extreme RSI (14-17) |
Unprecedented in our coverage — unusual institutional pressure |
| 100% earnings beat rate vs current 13x fwd P/E |
If guidance was conservative, significant re-rating upside |
| 7D declining from -8.4% → -1.3% |
Possible deceleration in selling — early signal worth watching |
Open Questions
- Has the Feb 12 low ($156.67) held, or has IQV broken down further?
- Is the Q4 cancellation trend in R&DS worsening or stabilizing?
- What is the AI platform revenue contribution timeline?
- Is the $13B debt a concern given rising refinancing costs?
- Current price and RSI unknown
Mistakes (If Applicable)
| Mistake |
Lesson |
| N/A — not entered yet |
RSI 25.5 "recovery" on 02/22 was a head fake — shows importance of sustained stabilization |
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.